Kyntra Bio (KYNB) Accumulated Expenses (2014 - 2026)

At the end of FY2025, Kyntra Bio reported Accumulated Expenses of $20.18 million, down 67.5% from FY2024.

• Annual Accumulated Expenses has declined for three straight years, with a five-year compound annual growth rate of -29.8% (FY2020 to FY2025).
• Across earlier years, Accumulated Expenses came in at $62.04 million in FY2024 (-53.4%), $132.99 million in FY2023 (-39.5%), $219.77 million in FY2022 (+27.3%) and $172.6 million in FY2021 (+45.9%).
• Quarterly Accumulated Expenses has ranged from $17.34 million in Q1 2026 to $219.77 million in Q4 2022 over the past five years.
• On a year-over-year basis, Accumulated Expenses has declined for nine consecutive quarters, with an average decline of 56.1% over the last eight quarters.
• Peak year-over-year performance for Accumulated Expenses in the last five years was growth of 69.7% in Q1 2022, against a decline of 82.9% in Q3 2025 at the low end.
• Per Business Quant, the preceding three quarters came in at $17.34 million (Q1 2026), $20.18 million (Q4 2025) and $25.78 million (Q3 2025).